Inimmune Group-06-2020

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy, infectious disease vaccines, and novel antibiotics for bacterial infections.

Inimmune was founded in early 2016 by Drs. Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter, and a team of 11 highly trained scientists. It is located in Missoula, MT, and works in close collaboration with the Center for Translational Medicine at the University of Montana as well as several industry and academia partners.

Inimmune was formed from an experienced, close-knit team of biotech/pharmaceutical industry professionals. This team of chemists, immunologists, and formulation scientists have been at the cutting edge of innovation for over 10 years as former GSK Vaccines scientists and investigators. They now are working to create new immunotherapies directed at making meaningful and lasting clinical impacts in the areas of allergy, autoimmunity, infectious disease, and cancer. Through its technology, assets, expertise, and favorable IP positioning, Inimmune is poised to stand up and become a leader in the fields of immunotherapy, infectious disease, and immuno-oncology.

Inimmune is headquartered in beautiful Missoula, Montana.